echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Express Screens Suitable Lung Cancer Patients for Blockbuster ADC Therapy, Liquid Biopsy Approved by FDA

    Express Screens Suitable Lung Cancer Patients for Blockbuster ADC Therapy, Liquid Biopsy Approved by FDA

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎Edited by WuXi AppTec Content Team

    Yesterday, the U.



    Lung cancer is the second most common type of cancer worldwide, with more than 2 million newly diagnosed patients in 2020


    Image source: Guardant Health official website


    In addition to Guardant, Thermo Fisher Scientific's Oncomine Dx was approved today as a companion test for Enhertu for this indication, which unlike Guardant requires the use of a tumor sample obtained from a tissue biopsy


    WuXi AppTec provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, covering chemical drug R&D and production, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and production and other fields



    ▲If you have any business needs, please long press to scan the QR code above, or

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.